NRG GY018: Pembrolizumab in Advanced Endometrial Cancer
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Shitanshu Uppal
MITO-7: Weekly chemotherapy in ovarian cancer
Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer
BEATcc: Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer
Atezolizumab plus bevacizumab and chemotherapy for
metastatic, persistent, or recurrent cervical cancer (BEATcc)
Publications Update # 42
New Year Resolutions, BEATcc trial exploring PD-L1 inhibitors in cervical cancer, chemotherapy regimens for older patients with ovarian cancer, and NRG-GY012 published.
Publications Update # 41
Happy Holidays and Happy New Year
GOG 281: Trametinib in recurrent low-grade serous ovarian cancer
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.
MIRASOL: Mirvetuximab in Platinum Resistant Cancer
Mirvetuximab Soravtansine (MIRV) in platinum resistant ovarian cancer
RHIP Framework for Change Management
RHIP framework can help with change management
EORTC-55994: Neoadjuvant Chemotherapy Followed by Surgery vs. Chemoradiation in Locally Advanced Cervical Cancer
EORTC and the trial from TATA memorial. Is neoadjuvant chemotherapy and surgery an alternative to chemoradiation in locally advanced cervical cancer?
DUO-E: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib in Advanced Endometrial Cancer
Does adding durvalumab (a PD-L1 inhibitor) and olaparib (a PARP inhibitor) to standard chemotherapy improve outcomes in advanced or recurrent endometrial cancer?